Comparing effects of weight loss by Liraglutide 3.0 mg with conventional liver fasting in non-alcoholic fatty liver disease before bariatric surgery

INTERVENTION: Trade Name: Saxenda Pharmaceutical Form: Solution for injection INN or Proposed INN: LIRAGLUTIDE CAS Number: 204656‐20‐2 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 6‐ CONDITION: Obesity and NAFLD can increase the risk and complexity of bariatric surgery up to 20%. Reducing the weight and liver size before bariatric surgery improves the operation area and reduces complications after the procedure. Therapeutic area: Body processes [G] ‐ Metabolic Phenomena [G03] PRIMARY OUTCOME: Main Objective: weight loss before bariatric surgery Primary end point(s): weight loss before bariatric surgery Secondary Objective: liver size reduction Timepoint(s) of evaluation of this end point: after 12 weeks SECONDARY OUTCOME: Secondary end point(s): liver size reduction Timepoint(s) of evaluation of this end point: after 12 weeks INCLUSION CRITERIA: BMI > 40 kg/m2, NAFLD‐diagnosis, Age: 18‐60 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range 62 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range